Literature DB >> 17010623

A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.

Takashi Kawasuji1, Tomokazu Yoshinaga, Akihiko Sato, Mitsuaki Yodo, Tamio Fujiwara, Ryuichi Kiyama.   

Abstract

We present a novel series of HIV integrase inhibitors, showing IC(50)s ranging from 0.01 to over 370microM in an enzymatic assay. Furthermore, pharmacophore modeling study for the inhibitors was carried out to elucidate the structure-activity relationships. Finally, we found a 3D-pharmacophore model, which is composed of a hydrophilic and a hydrophobic domain, providing valuable information for designing other novel types of integrase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010623     DOI: 10.1016/j.bmc.2006.08.044

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  9 in total

Review 1.  Authentic HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Christophe Marchand; Terrence R Burke; Yves Pommier; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

Review 2.  Computer tools in the discovery of HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

3.  A new biarylphosphine ligand for the Pd-catalyzed synthesis of diaryl ethers under mild conditions.

Authors:  Luca Salvi; Nicole R Davis; Siraj Z Ali; Stephen L Buchwald
Journal:  Org Lett       Date:  2011-12-19       Impact factor: 6.005

4.  Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.

Authors:  Takahiro Seki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Shigeru Miki; Chiaki Wakasa-Morimoto; Erika Akihisa; Koichiro Nakahara; Masanori Kobayashi; Mark R Underwood; Akihiko Sato; Tamio Fujiwara; Tomokazu Yoshinaga
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

5.  The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.

Authors:  Edward P Garvey; Brian A Johns; Margaret J Gartland; Scott A Foster; Wayne H Miller; Robert G Ferris; Richard J Hazen; Mark R Underwood; Eric E Boros; James B Thompson; Jason G Weatherhead; Cecilia S Koble; Scott H Allen; Lee T Schaller; Ronald G Sherrill; Tomokazu Yoshinaga; Masanori Kobayashi; Chiaki Wakasa-Morimoto; Shigeru Miki; Koichiro Nakahara; Takeshi Noshi; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

6.  In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors.

Authors:  Xiaoju Ni; Safwat Abdel-Azeim; Elodie Laine; Rohit Arora; Osamuede Osemwota; Anne-Geneviève Marcelin; Vincent Calvez; Jean-François Mouscadet; Luba Tchertanov
Journal:  Adv Virol       Date:  2012-07-05

Review 7.  Progress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity.

Authors:  Zahra Hajimahdi; Afshin Zarghi
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

8.  Design, Synthesis, Docking Study and Biological Evaluation of 4-Hydroxy-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide Derivatives as Anti-HIV Agents.

Authors:  Ali Imani; Sepehr Soleymani; Rouhollah Vahabpour; Zahra Hajimahdi; Afshin Zarghi
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

9.  Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.

Authors:  Felix DeAnda; Kendra E Hightower; Robert T Nolte; Kazunari Hattori; Tomokazu Yoshinaga; Takashi Kawasuji; Mark R Underwood
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.